The BREAKWATER trial showed improved response rates and survival with Braftovi, Erbitux, and chemotherapy in BRAF V600E-mutated metastatic colorectal cancer. FDA approval in December 2024 highlights ...

Dr. Cathy Eng discusses the importance of the Braftovi plus Erbitux FDA approval for treatment-naive BRAF V600E+ metastatic colorectal cancer. In December 2024, the United States Food and Drug ...

The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the disease.

MANILA, Philippines — The Mall of Asia Arena (MOA) has installed a brand new centerhung, an upgrade on the original jumbotron that hung at the venue since 2012. The installation of the "The Cube ...

These include the primary analysis of the pivotal overall survival (OS) and progression-free survival (PFS) results from the phase 3 BREAKWATER study investigating Braftovi (encorafenib)in combination ...

In the Philippines, few developments reflect this shift more clearly than the Mall of Asia (MOA) complex in Pasay City. Across a single district, MOA brings together a rare convergence ...

Their performance at the world-class SM Mall of Asia (MOA) Arena on May 5, marked their return to the country after over 17 years. For Filipino fans, Toto’s concert was a long-awaited chance to ...

Between 2020 and 2024, 53 combination therapies applied for expanded reimbursement, but only one cross-company case (Braftovi and Erbitux for colorectal cancer) was approved, according to data ...

Held at the SM Mall of Asia Arena, the Autism Society Philippines’ Angels Walk 2025 brought together over 40,000 advocates in a nationwide movement for autism appreciation, accommodation, and ...

On May 2, 2025, the highly anticipated competition unfolded at the SM Mall of Asia (MOA) Arena, drawing in a trailblazing crowd of supporters from across the country who came to support their ...

Two-drug therapy with Braftovi and Erbitux also performed well, with an OS of 8.4 months. Kopetz tweeted that the response rates in second-line patients was 34% for the triplet, 22% for the ...